Sex/Gender -Based Pharmacology and Statin Utilization Amongst Elderly Patients with Diabetes

Abstract

Purpose: The purpose of this study was to explore the ten-year trends in utilization of bioequivalent doses of statin amongst elderly patients with diabetes according to sex/ gender in Ontario, Canada. Methods:A cohort of patients with diabetes (>65 years) was constructed using the Ontario Diabetes Database Statin utilization data (2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012) was obtained from the Ontario Drug Benefit Program for both women and men. Bioequivalent doses for statins were calculated according to the dosing conversion factor in therapeutic interchange programs in clinical practice. Utilization pattern of high potency (Atorvastatin and Rosuvastatin) vs. low potency statins (Simvastatin, Lovastatin, Fluvastatin, Pravastatin) were also analyzed. Results:The average bioequivalent Simvastatin utilization in 2003 was 29.22 mg/day for women and 30.35 mg/day for men. By 2008, this gap in dosing was higher for both women and men and by 2013 it had increased to 47.75 mg/day for women and 52.98 mg/day for men. For average number of day supply per year, there was no significant trend of changes over the 10-year period, although the use of high potency statins increased significantly (P<0.001) for both women and men. No differences were seen for sex/gender; either for the 10-year period or for each year.Conclusions: There has been significant increase in bioequivalent statin utilization amongst elderly patients with diabetes in Ontario; for both men and women. In a publiclyfunded healthcare system such as Ontario, there were no sex/gender differences in the utilization of high potency statin (Atorvastatin and Rosuvastatin) amongst elderly patient with diabetes.

Impact of the Diabetes Canada Guideline Dissemination Strategy on the Prescription of Vascular Protective Medications: A Retrospective Cohort Study, 2010–2015

“…Multiple studies examining vascular protective agents in Canada have shown an increase in statins and ACEIs/ARBs prescribed and used over the past two decades (10)(11)(12). Estimates from one Canadian province (Ontario) suggest that statin prescriptions in patients with diabetes aged .65 years have increased 53% from 1996 to 2010 and ACEI/ARB prescriptions have increased by 22% over a 6-year period (1995-2001) (11,12).…”